Vaginal misoprostol for abortion at 10-13 weeks' gestation.
OBJECTIVE
The effectiveness and safety of misoprostol have been reported for abortion up to 22 weeks' gestation. The objective of this study was to demonstrate the effectiveness and safety of self-administration of misoprostol every 12 h, without the need of postexpulsion systematic curettage, in late first-trimester abortions (10-13 weeks' gestation).


METHODS
A group of 180 women with gestations from 64 to 91 days, self-administered 800 micrograms of vaginal misoprostol every 12 h for a maximum of three doses without performing postexpulsion systematic preventive curettage. Outcome measures included successful abortion (complete and incomplete abortion without requiring a surgical procedure), side-effects, mean expulsion time and vaginal bleeding.


RESULTS
Successful abortion occurred in 153/180 (85%) subjects (95% confidence interval (CI) 79-90). The decrease of hemoglobin was statistically significant (p = 0.0001) but clinically unimportant: 12.1 mg/dl (SD 1.1) before treatment and 11.7 mg/dl (SD 1.1) afterwards. The mean expulsion time for patients who aborted after the first dose was 8.3 +/- 3.6 h (median 8 h, range 2-12 h). Vaginal bleeding lasted 6 +/- 3 days, spotting 7 +/- 3 days and total bleeding 13 +/- 4 days. The median dose of misoprostol administered was 1780 micrograms (range 1400-3000 micrograms).


CONCLUSIONS
The high degree of acceptability, its efficacy and the fact that postabortion systematic curettage was not needed make misoprostol a suitable alternative to the currently available methods for termination of pregnancy at 10-13 weeks' gestation.
Carbonell
J L
JL
Hospital Docente Gineco-Obstétrico Eusebio Hernández (Maternidad Obrera), Ciudad de la Habana, Cuba.
Varela
L
L
Velazco
A
A
Tanda
R
R
Sánchez
C
C
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000028:Abortion, Induced; D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D003462:Cuba; D004305:Dose-Response Relationship, Drug; D004522:Educational Status; D005006:Ethnicity; D005260:Female; D006760:Hospitalization; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage*; D010298:Parity; D017060:Patient Satisfaction; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D012646:Self Administration
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol